Clinical Trials

75 enrolled

Gynecologic

Recurrence, Endometrial Neoplasms

NCT03643510 2026-03-16

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

Phase 2 Completed

28 enrolled

Adenocarcinoma of Endometrium

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05940493 2026-03-13

Abemaciclib in Newly Diagnosed Meningioma Patients

72 enrolled

Meningioma

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT04391595 2026-03-06

LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients

42 enrolled

Glioblastoma, Glioma

NCT03531645 2026-03-05

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

18 enrolled

Other neoplasm

Malignant Neoplasms of Female Genital Organs

NCT05708235 2026-03-05

MiRaDoR

976 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms, Neoplasm, Residual

NCT07428018 2026-03-05

VIOLET

150 enrolled

Breast Neoplasms

NCT02523014 2026-03-04

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

124 enrolled

Meningioma

NCT03994796 2026-03-04

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Phase 2 Suspended

186 enrolled

Phase 2 Enrolling by invitation

Brain Neoplasms, Neoplasm Metastasis

NCT07441369 2026-03-02

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer

16 enrolled

Gastrointestinal

Liver Metastases From Colorectal Cancer (mCRC)

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Phase 1 Active not recruiting

9 enrolled

Genitourinary

Prostatic Neoplasms

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT03130439 2026-02-20

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

Phase 2 Terminated

27 enrolled 17 charts

Breast Neoplasms

NCT04751929 2026-02-20

Abemaciclib With or Without Atezolizumab for mCRPC

Phase 2 Not yet recruiting

19 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT07410559 2026-02-18

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

189 enrolled

Breast Neoplasms

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT06678269 2026-02-12

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Phase 1 Recruiting

28 enrolled

Breast Neoplasms

NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

Phase 2 Not yet recruiting

32 enrolled

Gynecologic

Endometrial Neoplasms

NCT07340541 2026-02-09

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04923542 2026-02-06

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

Phase 1/2 Recruiting

31 enrolled

Brain Neoplasms

NCT04481113 2026-01-29

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Phase 1 Completed

8 enrolled

Unilateral Breast Neoplasms

NCT05305924 2026-01-28

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

28 enrolled

ER-Positive Breast Cancer

NCT05933395 2026-01-20

GERTRUDE

135 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Breast Neoplasms

NCT06835972 2026-01-15

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Phase 1/2 Recruiting

43 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT03891784 2026-01-14

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

EndocrineGastrointestinalNET

20 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

NCT04169074 2026-01-14

Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)

Phase 2 Terminated

7 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT04584853 2026-01-14

POETIC-A

Phase 3 Active not recruiting

123 enrolled

Breast Cancer Female

NCT06169371 2026-01-14

BRE-09

Phase 4 Recruiting

50 enrolled

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05501704 2026-01-07

ETHAN - ET for Male BC

60 enrolled

Breast Neoplasms, Male

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer